These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 20206139)

  • 81. Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver.
    Hayashi S; Kawaguchi H; Watanabe T; Miyawaki I; Fukami T; Nakajima M
    Xenobiotica; 2023 Apr; 53(4):241-247. PubMed ID: 37305902
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.
    Madani S; Paine MF; Lewis L; Thummel KE; Shen DD
    Pharm Res; 1999 Aug; 16(8):1199-205. PubMed ID: 10468020
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations.
    Bapiro TE; Hasler JA; Ridderström M; Masimirembwa CM
    Biochem Pharmacol; 2002 Nov; 64(9):1387-98. PubMed ID: 12392820
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Potential role of CYP2D6 in the central nervous system.
    Cheng J; Zhen Y; Miksys S; Beyoğlu D; Krausz KW; Tyndale RF; Yu A; Idle JR; Gonzalez FJ
    Xenobiotica; 2013 Nov; 43(11):973-84. PubMed ID: 23614566
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
    Blake CM; Kharasch ED; Schwab M; Nagele P
    Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
    Ramamoorthy Y; Yu AM; Suh N; Haining RL; Tyndale RF; Sellers EM
    Biochem Pharmacol; 2002 Jun; 63(12):2111-9. PubMed ID: 12110370
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
    Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
    J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Tissue distribution, metabolism and effects of bufotenine administered to rats.
    Fuller RW; Snoddy HD; Perry KW
    Neuropharmacology; 1995 Jul; 34(7):799-804. PubMed ID: 8532147
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates.
    Komura H; Iwaki M
    Xenobiotica; 2005 Jun; 35(6):575-87. PubMed ID: 16192109
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effect of 22 Novel Cytochrome P450 2D6 (CYP2D6) Variants Found in the Chinese Population on Hemangeol Metabolism In Vitro.
    Liang B; Zhan Y; Huang X; Gu E; Dai D; Cai J; Hu G
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):759-765. PubMed ID: 26542054
    [TBL] [Abstract][Full Text] [Related]  

  • 91. CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes.
    Dragoni S; Materozzi G; Pessina F; Frosini M; Marco JL; Unzeta M; Sgaragli G; Valoti M
    J Pharm Pharm Sci; 2007; 10(4):473-85. PubMed ID: 18261369
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
    Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
    Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
    Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
    J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
    [TBL] [Abstract][Full Text] [Related]  

  • 94. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
    Davis AK; So S; Lancelotta R; Barsuglia JP; Griffiths RR
    Am J Drug Alcohol Abuse; 2019; 45(2):161-169. PubMed ID: 30822141
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization.
    Gilham DE; Cairns W; Paine MJ; Modi S; Poulsom R; Roberts GC; Wolf CR
    Xenobiotica; 1997 Jan; 27(1):111-25. PubMed ID: 9041683
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity.
    Muroi Y; Saito T; Takahashi M; Sakuyama K; Niinuma Y; Ito M; Tsukada C; Ohta K; Endo Y; Oda A; Hirasawa N; Hiratsuka M
    Drug Metab Pharmacokinet; 2014; 29(5):360-6. PubMed ID: 24647041
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
    Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
    [TBL] [Abstract][Full Text] [Related]  

  • 98. In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone.
    Su Y; Zhan YY; Wang BF; Wang SC; Dai DP; Hu GX; Lin H; Lian QQ; Cai JP
    Drug Test Anal; 2017 Feb; 9(2):216-220. PubMed ID: 26968424
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis.
    Yu AM; Qu J; Felmlee MA; Cao J; Jiang XL
    Drug Metab Dispos; 2009 Jan; 37(1):170-7. PubMed ID: 18832475
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
    Niwa T; Shizuku M; Yamano K
    Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.